TABLE 1.
Clinico-pathological characteristics of the study cohort.
| Median | IQR | |
| Age (years) | 63 | 52–71 |
| ER (%) | 95 | 90–95 |
| PR (%) | 50 | 20–75 |
| N | % | |
| Age | ||
| <50 | 10 | 20 |
| ≥50 | 39 | 80 |
| ESR1 status | ||
| Wild type | 40 | 82 |
| Mutated | 7 | 14 |
| Not evaluable | 2 | 4 |
| PIK3CA status | ||
| Wild type | 36 | 72 |
| Mutated | 11 | 22 |
| Not evaluable | 2 | 4 |
| Liver involvement | ||
| No | 35 | 73 |
| Yes | 14 | 27 |
| Lung involvement | ||
| No | 38 | 78 |
| Yes | 11 | 22 |
| CNS involvement | ||
| No | 49 | 100 |
| Yes | 0 | 0 |
| Bone involvement | ||
| No | 17 | 35 |
| Yes | 32 | 65 |
| Lymph nodes involvement | ||
| No | 32 | 65 |
| Yes | 17 | 35 |
| Soft tissue involvement | ||
| No | 45 | 92 |
| Yes | 4 | 8 |
| First-line treatment agents | ||
| AI single agent | 1 | 2 |
| Fulvestrant single agent | 2 | 4 |
| AI and CDK4/6i | 34 | 71 |
| Fulvestrant and CDK4/6i | 11 | 23 |
IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; ESR1, estrogen receptor 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha.